TG Therapeutics reported quarterly EPS of $0.17, missing the Zacks Consensus Estimate of $0.23 by $0.06 per share, though results improved from $0.03 a year ago. The miss is a modest negative for the stock and may pressure near-term sentiment, but the article provides no additional operational details or guidance changes.
TG Therapeutics reported quarterly EPS of $0.17, missing the Zacks Consensus Estimate of $0.23 by $0.06 per share, though results improved from $0.03 a year ago. The miss is a modest negative for the stock and may pressure near-term sentiment, but the article provides no additional operational details or guidance changes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.30
Ticker Sentiment
